Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Adductor Canal Block in Outpatient Total Knee Arthroplasty
NCT05100706Completed
- Sponsor
- University of Toronto
- Start
- Oct 2023
- Primary completion
- Jan 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in acute pain (2 arms), sponsored by University of Toronto. Primary endpoint: Quality of Recovery 15 score at Day 3. Started Oct 2023; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT05100706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05100706.